within Pharmacolibrary.Drugs.ATC.G;

model G02CX02
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.33,
    Cl             = 0.0017,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.011,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0085,
    Tlag           = 3000
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>G02CX02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Flibanserin is a non-hormonal, multifunctional serotonin agonist and antagonist used for the treatment of premenopausal women with hypoactive sexual desire disorder (HSDD). It is approved by the FDA for this indication and is marketed under the brand name Addyi.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy premenopausal female subjects after administration of a single 100 mg oral dose under fasting conditions.</p><h4>References</h4><ol><li><p>Johnson-Agbakwu, C, et al., &amp; Greenblatt, DJ (2018). Effects of Flibanserin on the Pharmacokinetics of a Combined Ethinylestradiol/Levonorgestrel Oral Contraceptive in Healthy Premenopausal Women: A Randomized Crossover Study. <i>Clinical therapeutics</i> 40(1) 64–73. DOI:<a href=&quot;https://doi.org/10.1016/j.clinthera.2017.08.021&quot;>10.1016/j.clinthera.2017.08.021</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/29198449/&quot;>https://pubmed.ncbi.nlm.nih.gov/29198449</a></p></li><li><p>Robinson, K, et al., &amp; Carris, NW (2016). First Pharmacological Therapy for Hypoactive Sexual Desire Disorder in Premenopausal Women: Flibanserin. <i>The Annals of pharmacotherapy</i> 50(2) 125–132. DOI:<a href=&quot;https://doi.org/10.1177/1060028015622182&quot;>10.1177/1060028015622182</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/26692273/&quot;>https://pubmed.ncbi.nlm.nih.gov/26692273</a></p></li><li><p>Alharbi, WS, et al., &amp; Naguib, MJ (2022). Spanlastics as a Potential Platform for Enhancing the Brain Delivery of Flibanserin: In Vitro Response-Surface Optimization and In Vivo Pharmacokinetics Assessment. <i>Pharmaceutics</i> 14(12) –. DOI:<a href=&quot;https://doi.org/10.3390/pharmaceutics14122627&quot;>10.3390/pharmaceutics14122627</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36559120/&quot;>https://pubmed.ncbi.nlm.nih.gov/36559120</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end G02CX02;
